CST Announces Expansion of Studies with AstraZeneca
Complete the form below to unlock access to ALL audio articles.
Cell Signaling Technology, Inc. has announced a second agreement with AstraZeneca under which an expanded pilot study will be performed with CST's PhosphoScan™ technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds.
CST's PhosphoScan™ proteomics technology is a patent-pending strategy that is designed to enable the discovery of drug target phospho-profiles (Phospho-Signatures™) in cells and disease tissues.
The PhosphoScan™ technology involves immunoaffinity purification and mass spectroscopy and was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)).
The Phospho-Signatures™ discovered with PhosphoScan™ may enable biomarker assays for target validation and therapeutic kinase inhibitor clinical development.
"Our expanded PhosphoScan™ research program with AstraZeneca illustrates the value of CST's phosphoproteomics capabilities to our partner, and we are confident that the program deliverables will continue to add value to AstraZeneca's kinase inhibitor development programs," said Christopher Bunker, CST's Director of Business Development.
"With PhosphoScan™, we can deliver focused, in-depth Phospho-Signatures™ of kinase inhibitor response in disease cells and tissues, and identify biomarkers of kinase target activation and inhibition."
"AstraZeneca can also benefit, under our agreement, from CST's expertise in antibody and immunoassay development to translate PhosphoScan™ discoveries into clinical biomarker assays."
